source
- Angelini to acquire Catalyst Pharmaceuticals for $4.1 billion, adding rare CNS drug portfolioAngelini Pharma announced it will purchase Catalyst Pharmaceuticals in a cash transaction valued at about $4.1 billion. The agreement pays $31.50 per Catalyst share, representing a 21% premium to…
- FDA approves small-molecule dasatinib formulation, expanding CML treatment optionsDr Michael J. Mauro explained that the FDA gave its nod in November 2025 to a generic, small-molecule version of dasatinib, the drug sold as Sprycel, for adult patients with Philadelphia-positive c…